Our pipeline is rich with opportunity

OncoResponse antibodies to key targets reverse and relieve immunosuppression in the tumor microenvironment to enhance responses from immunotherapy to greater cures.  OR-2805 reprograms M2-like TAMs leading to increased adaptive T-cell activation and proliferation.